Genmab A/S(Nasdaq: GMAB)today announced updated results from two ongoing clinical trials evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging antibody administered subcutaneously, ...
These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the transformative potential of CASGEVY,” said Carmen Bozic, M.D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback